

Vida Vital



VIDA-VITAL

AI-Powered Breast Health Screening

22 Years NASA-Validated | Legally Verified Patentability

<https://vida-vital.com/>,
limited IOS, BETA release: <https://testflight.apple.com/join/U5ZjfNhc>
Beta release Android on demand.
Email: dr.jonas@vida-vital.com
WhatsApp: +49 175 3413013

INVESTOR PITCH DECK | April 2026

The Problem



2.3 million

new breast cancer cases annually

70%

of women skip regular screenings

Barriers:

- • Cost (\$250-400 per mammogram)
- • Access (infrastructure, wait times)
- • Discomfort & privacy concerns
- • Limited availability in underserved regions

The Solution



VIDA-VITAL

Smartphone NIR imaging + neuromimetic AI identify vascular anomalies

- ✓ \$27/year (vs. \$250+ mammogram)
- ✓ Instant results, private
- ✓ No equipment, no clinics
- ✓ FDA-exempt (wellness category)

How It Works:

1. User takes smartphone photo (NIR)
2. Neuromimetic AI analyzes vascular patterns
3. App recommends: 'See specialist' or 'WHO annual checkup'

Recommendation-only. No diagnosis. Ever.

The Unfair Advantage



22 Years NASA R&D + Legal Patent Validation

NASA Heritage

- ✓ Neuromimetic neural networks
- ✓ Validated for satellite imaging
- ✓ Advances NASA RETINET patent
- ✓ Zero training required (not GPU AI)

22 years vs. competitors' 1-2 years

Legal Patentability Verified

Exhaustive legal analysis confirms:

- ✓ Novel (not in prior art)
- ✓ Non-obvious (unique NIR + neuromimetic + skin surface)
- ✓ Utility proven (32-woman pilot 100% sensitive)

★ See Annex 1: 17-page legal patentability review

Regulatory Moat: Legally Documented

No FDA/EMA approval needed — Enforcement discretion verified

FDA (USA)

- ✓ General Wellness (2026 reaffirmed)
- ✓ Enforcement discretion = exempt
- ✓ Immediate commercialization

EMA (Europe)

- ✓ Outside MDR scope (wellness only)
- ✓ No CE marking required
- ✓ GDPR compliant (images deleted)

PERMANENT COMMITMENT:

VIDA-VITAL will NEVER diagnose directly disease — even after any future approvals.

This is legally binding and fundamental to regulatory classification.

★ See Annex 2: FDA/EMA legal compliance analysis

Business Model: Wellness → Medical

The Proven 23andMe Playbook

Phase 1: Wellness (Now)

Months 0-24

- • \$27/year DTC
- • FDA-exempt (enforcement discretion)
- • Prove product-market fit
- • *Closed beta on TestFlight (iOS/Android); funding required for clinical efficacy study (200 women), not product development.*

Phase 2: Medical (Optional)

Months 24-36+ (if pursued)

- • \$50/user B2B (insurance)
- • Still recommendation-only (not diagnostic)
- • Enterprise distribution via insurers

Proven Precedents:

- • 23andMe: Ancestry → FDA reports (\$2.5B valuation)
- • Apple Watch: Heart rate → FDA ECG (dominant)
- • AliveCor: App → FDA device (~\$500M exit)
- • Natural Cycles: Tracking → FDA contraceptive

5-Year Financial Projections



Year	Year 1	Year 2	Year 3	Year 4	Year 5
Wellness Users	75K	195K	345K	595K	1,185K
Medical Users	—	12.5K	81K	296K	600K
Net Revenue	\$1.0M	\$3.3M	\$8.4M	\$21.1M	\$42.5M
EBITDA	(\$877K)	(\$935K)	\$928K	\$8.2M	\$20.9M
EBITDA Margin	(86.8%)	(28.0%)	11.0%	38.9%	49.0%

Conservative model: Revenue CAGR 154.8% | Profitable Year 3

★ *Based on uploaded model metrics — credible, defensible projections*

Investment Returns



\$80M

NPV @ 35%

134%

IRR (5-year)

71x

Return Multiple

\$375M

Year 5 Enterprise Value (8x revenue)

Conservative, credible model validated by legal due diligence

Angel Round: Two Options



Option A: Staged

(Lower risk)

Initial: \$120,000

If positive: +\$300,000

- ✓ 100 women Phase 1 (3 months)
- ✓ Go/No-Go at Month 3
- ✓ 61% less risk if trial fails

Total if positive: \$420K

Option B: Full Trial

(Single commitment)

Upfront: \$365,000

- ✓ Full 300-woman trial (9 months)
- ✓ No checkpoint
- ✓ \$20K cheaper than Option A
- ✓ Fastest to Series A

Total: \$365,000

★ Patent filing automatic at Month 3 if positive (both options)

Competitive Landscape



Feature	VIDA-VITAL	Thermalytix	iBreastExam	Cyrcadia
Technology	NIR + neuromimetic	Thermal imaging	Physical exam	Wearable patch
Equipment	Smartphone only	Thermal camera	Special device	24hr patch
Regulatory	FDA-exempt (wellness)	FDA clearance req'd	FDA clearance req'd	FDA clearance req'd
IP Moat	22yr NASA + legal verified	1-2 years	1-2 years	1-2 years
User Cost	\$27/year	\$50-100/scan	\$40-80/exam	\$250/month

Our advantages: No equipment, FDA-exempt, 22-year IP moat, legally validated

Founder team



Ronald Jonas, CEO
PhD in Cognitive Sciences, Neural networks, Neuromorphic neural networks, Mathematical complexity, **École Polytechnique, 30+ years in AI** and medical imaging. 25 years developing cancer-related imaging algorithms, now applied to scalable smartphone technology.



Emilio Sacristán, CBO
PhD biomedical engineer, **National Science Prize laureate** (Mexico) for developing an artificial heart. Professor and medical device innovator, **CI3M** director, leading scientific strategy and commercialization.



Max Dmitrychenko, CTO
25+ years of experience as a director at **Intel and Apple**. Expert in hardware optimization and system performance, leading VIDA-VITAL's technical scalability.



Ana Paula Aravena, CMO
Degree in Public Relations and Marketing, 4+ years as **the strategic interface between medical AI technology and feminine sensibility** at VIDA-VITAL. Expert in women's health advocacy and global market expansion, leading empathetic brand strategy and user-centric innovation.



Felipe Calleja, CDO
Commercial Engineer, MBA, and Graphic Designer with 14+ years in digital design, e-commerce, and e-learning. **Expert in SEM/SEO and digital channel optimization**, leading VIDA-VITAL's design strategy and digital transformation.

Why We Win



1

Unassailable IP Moat

22-year NASA heritage + legal patentability verification (Annex 1)

2

Regulatory Certainty

FDA/EMA enforcement discretion documented (Annex 2) — no approval needed

3

Capital Efficiency

Performance marketing (zero upfront CAC) + recommendation-only (low liability)

4

Proven Playbook

23andMe, Apple Watch, AliveCor all used wellness → medical transition

The Ask

Angel Round: **\$120K-\$365K**

Series A (Year 2): **\$5M**

Legal due diligence complete. IP secured. Regulatory path clear.

Let's save lives and generate exceptional returns.